Premium
Melatonin or silymarin reduces maneb‐ and paraquat‐induced Parkinson’s disease phenotype in the mouse
Author(s) -
Singhal Naveen Kumar,
Srivastava Garima,
Patel Devendra Kumar,
Jain Swatantra Kumar,
Singh Mahendra Pratap
Publication year - 2011
Publication title -
journal of pineal research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.881
H-Index - 131
eISSN - 1600-079X
pISSN - 0742-3098
DOI - 10.1111/j.1600-079x.2010.00819.x
Subject(s) - melatonin , paraquat , cyp2e1 , tyrosine hydroxylase , endocrinology , lipid peroxidation , medicine , oxidative stress , dopaminergic , neurodegeneration , pharmacology , dopamine , chemistry , biology , biochemistry , cytochrome p450 , metabolism , disease
Oxidative stress is reported as one of the most widely accepted mechanisms of maneb (MB)‐ and paraquat (PQ)‐induced nigrostriatal dopaminergic neurodegeneration leading to the Parkinson’s disease (PD) phenotype. The study investigated the effects of silymarin, an antioxidant of plant origin, and melatonin, an indoleamine produced in all species, in MB‐ and PQ‐induced mouse model of PD. The mice were treated intraperitoneally daily with silymarin (40 mg/kg) or melatonin (30 mg/kg) along with respective controls for 9 wk. Subsets of these animals were also treated with MB (30 mg/kg) and PQ (10 mg/kg), twice a week, for 9 wk, 2 hr after silymarin/melatonin treatment. Locomotor activities along with striatal dopamine content, tyrosine hydroxylase (TH) immunoreactivity, number of degenerating neurons, lipid peroxidation and nitrite content were estimated. Additionally, mRNA expression of vesicular monoamine transporter, cytochrome P‐450 2E1 (CYP2E1), and glutathione‐S‐transferase A4‐4 (GSTA4‐4), catalytic activities of CYP2E1 and GSTA4‐4 and protein expressions of unphosphorylated and phosphorylated p53 (p53 and P‐p53), Bax and caspase 9 were measured in control and MB‐ and PQ‐treated mice with either silymarin or melatonin treatments. Silymarin/melatonin significantly offset MB‐ and PQ‐mediated reductions in locomotor activities, dopamine content, TH immunoreactivity, VMAT 2 mRNA expression and the expression of p53 protein. Silymarin/melatonin attenuated the increases in lipid peroxidation, number of degenerating neurons, nitrite content, mRNA expressions of cytochrome P‐450 2E1 (CYP2E1) and GSTA4‐4, catalytic activities of CYP2E1 and GST and P‐p53, Bax and caspase 9 protein expressions. The results demonstrate that silymarin and melatonin offer nigrostriatal dopaminergic neuroprotection against MB‐ and PQ‐induced PD by the modulation of oxidative stress and apoptotic machinery.